Recent efforts in structure-guided probe optimization have led to the establishment of a set of DOT1L-inhibitors with improved pharmacologic properties including attenuated plasma concentrations and oral bioavailability that were recently reported to have promising pre-clinical activity in patient-derived xenograft models of AML [172,173]. This evidence concerns the gene DOT1L and acute myeloid leukemia.